Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate the safety and the efficacy of a single
treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin
complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG)), used
for the improvement in the appearance of moderate to severe glabellar lines (the lines
between the eyebrows).
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA